Skip to content

InvEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease

invEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06713512
Acronym
ESSENTIAL
Enrollment
100
Registered
2024-12-03
Start date
2024-12-01
Completion date
2028-11-01
Last updated
2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Chronic Obstructive Lung Disease, Estrogen Deficiency, Respiratory Ilness

Keywords

Asthma, COPD

Brief summary

This study aims to understand the role of oestrogen in patients with asthma and Chronic Obstructive Pulmonary Disorder (COPD). Therefore, what is the effect of oestrogen in these participants compared to controls (those without disease). The study hypothesises that oestrogen loss in patients with asthma and COPD causes accelerated lung function decline and changes to lung structure. It will investigate if this is mediated by inflammation, immune host response or elastin and collagen changes. It is an observational prospective cohort study aiming to recruit healthy controls, and people with asthma or COPD), and/or the menopause.

Detailed description

The investigators are investigating the effect of oestrogen and oestrogen loss on the lungs. This is important to because lung diseases are a growing problem globally. In people suffering from Asthma and chronic obstructive pulmonary disease (COPD), women are more likely to die from lung disease than men. The researchers believe this global difference is due to sex hormones. Women have more oestrogen than men. Other studies have shown that oestrogen affects the lungs through the immune system. The researchers want to know the effect that oestrogen has on the lungs in people suffering from Asthma and COPD by comparing this to people with no lung disease. The researchers are also particularly interested in what happens at the point where women lose oestrogen naturally, which is the menopause. They want to understand the effect of oestrogen in younger women and compare this to women who have experienced the menopause. This is an observational study. Therefore, the participants will have a baseline visit and another subsequent visit (or multiple visits which are optional) and the researchers will compare the changes in their oestrogen levels, lung function and immune system response. To understand the differences mentioned above in the body we require samples and questionnaires to be filled out at face-to-face visits. All participants will be given the opportunity to opt into different streams of visits which vary between 12 months and 24 months.

Interventions

OTHERNo intervention

No Intervention

Sponsors

Guy's and St Thomas' NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

1. Men and women aged > 18 years. 2. For female participants: pre-menopausal, peri-menopausal and post-menopausal women can all be included. 3. Participants willing and able to give informed consent for participation in the study. 4. Healthy controls <10 pack year history (participants without Asthma or COPD).

Exclusion criteria

1. Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus. 2. Alcohol or recreational drug abuse, is defined as when the use is harmful as per NHS definition. 3. History of psychiatric, medical, or surgical disorders. 4. Pregnant 5. Unable to provide written informed consent 6. History of advanced medical conditions with an expected prognosis of < 3 years. 7. Patients with a history of active cancer. 8. Patients on long term oxygen (ambulatory oxygen).

Design outcomes

Primary

MeasureTime frameDescription
Lung Function (FEV1 change from baseline)Through study completion, minimum of 1 yearLung function measures the volume of air exhaled at specific time points during complete exhalation by force, which is preceded by a maximal inhalation.

Secondary

MeasureTime frameDescription
The COPD Assessment Test (CAT)Through study completion, minimum of 1 yearThe COPD Assessment Test (CAT) is a questionnaire for people with Chronic Obstructive Pulmonary Disease (COPD). It is designed to measure the impact of COPD on a person's life, and how this changes over time
Asthma Control Questionnaire (ACQ)Through study completion, minimum of 1 yearA simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.
OscillometryThrough study completion, minimum of 1 yearOscillometry is a technique that measures the mechanical impedance of the respiratory system, or how well the lungs are functioning.
EQ-5D-5LThrough study completion, minimum of 1 yearThe EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The Greene Climacteric Scale (GCS)Through study completion, minimum of 1 yearis a questionnaire that helps to determine the severity of menopausal symptoms.
Asthma Quality of Life Questionnaire (AQLQ)Through study completion, minimum of 1 yearA disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease. The instrument should not be confused with the measure developed by Marks GB and colleagues, which carries the same name.

Countries

United Kingdom

Contacts

Primary ContactGill Radcliffe Ms, MRes
gillian.radcliffe@gstt.nhs.uk+442071888070
Backup ContactChris Mwasuku
Christine.Mwasuku@gstt.nhs.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026